COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines.
Ishan GargRahul ShekharAbu Baker SheikhSuman PalPublished in: Infectious disease reports (2021)
Coronavirus 2019 (COVID-19) has created a global pandemic that is devastating human lives, public healthcare systems, and global economies. Multiple effective and safe COVID-19 vaccines have been developed at an unprecedented speed due to the efforts of the scientific community, and collaboration between the federal government and pharmaceutical companies. However, the continued exclusion of pregnant and lactating women from the COVID anti-viral and vaccine trials has created the paradox of a lack of empirical evidence in a high-risk population. Based on the experience of similar prior vaccines, animal developmental and reproductive toxicology studies, and preliminary findings from human studies, various healthcare professional advisory committees (Advisory Committee on Immunization Practices, American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine, and Academy of Breastfeeding Medicine) have issued guidance supporting COVID-19 vaccination in pregnant and lactating women. In this article, we summarize the available data on the efficacy and safety profile of COVID-19 vaccination in pregnant and lactating women, review the challenges of vaccine hesitancy, and include recommendations for healthcare providers.
Keyphrases
- sars cov
- coronavirus disease
- healthcare
- polycystic ovary syndrome
- respiratory syndrome coronavirus
- pregnancy outcomes
- endothelial cells
- pregnant women
- heat stress
- primary care
- dairy cows
- mental health
- machine learning
- type diabetes
- body mass index
- physical activity
- preterm infants
- skeletal muscle
- metabolic syndrome
- adipose tissue
- insulin resistance
- electronic health record
- quality improvement
- clinical practice
- breast cancer risk
- artificial intelligence
- health insurance